Hydrochlorothiazide (HCTZ) is a diuretic primarily used to treat hypertension and edema. The drug's supply chain involves multiple generic manufacturers, active pharmaceutical ingredient (API) producers, and formulation companies globally.
Major API Manufacturers
Company
Country
Estimated Capacity
Notes
Teva Pharmaceutical Industries
Israel
Large-scale production, global distribution
One of the world's largest API producers, with significant HCTZ output.
Jiangsu Hengrui Medicine
China
Significant capacity
Supplies API mainly for domestic and export markets.
Zhejiang Huahai Pharmaceutical
China
Major API producer
Known for large-scale production and export of HCTZ API.
Solara Active Pharma Sciences
India
Moderate capacity
Focuses on high-quality APIs for global markets.
Key Formulation and Finished-Goods Suppliers
Company
Country
Market Focus
Notes
Amneal Pharmaceuticals
USA
Generics for North America
Produces finished HCTZ tablets.
Mylan (now Viatris)
Global
North America, Europe
Large portfolio of generic cardiovascular drugs, including HCTZ.
Sandoz (Novartis)
Global
Europe, International
Offers HCTZ as part of its generic portfolio.
Aurobindo Pharma
India
Global
Supplies HCTZ tablets to multiple markets.
Teva Pharmaceuticals
Global
North America, Europe
Provides generic HCTZ formulations.
Market Dynamics and Supply Chain Considerations
China and India dominate API production for hydrochlorothiazide, accounting for over 80% of total API exports (World Health Organization, 2022).
Regulatory approvals and quality standards influence the availability of APIs and finished drugs.
Supply disruptions have occurred during COVID-19, impacting price and availability.
Regulatory and Patent Landscape
Hydrochlorothiazide is off-patent globally, leading to multiple generic manufacturers.
Regulatory pathways involve Abbreviated New Drug Application (ANDA) submissions in the U.S., and equivalents in other regions.
Quality standards adhere to USP, EP, and JP pharmacopoeias, regulated by agencies such as the FDA, EMA, and PMDA.
Supply Security and Risks
Dependence on API imports from China and India introduces supply chain risks.
Quality issues or regulatory restrictions in Key API-producing countries can disrupt supply.
Increased regional manufacturing capacity aims to mitigate geographic risks.
Summary
The hydrochlorothiazide supply chain features a diverse set of global API producers mainly located in China and India, complemented by an active network of finished drug formulators across North America, Europe, and India. The API market's size and concentration pose supply risks, mitigated by regional manufacturing expansions and the drug’s patent expiry.
Key Takeaways
API production is concentrated in China and India, with over 80% share.
A broad network of generic formulators supplies finished hydrochlorothiazide tablets worldwide.
Supply disruptions during COVID-19 highlight vulnerability in API dependency.
Regulatory pathways facilitate market entry for multiple manufacturers, increasing competition.
Geographic diversification reduces supply chain risks but remains a concern due to quality and regulatory issues.
FAQs
Who are the largest API producers for hydrochlorothiazide?
Teva, Jiangsu Hengrui, Zhejiang Huahai, and Solara are among the leading API producers.
Are there any patent restrictions affecting hydrochlorothiazide suppliers?
Hydrochlorothiazide is off-patent globally, allowing multiple generics manufacturers to produce and sell formulations.
What regions dominate the hydrochlorothiazide finished drug market?
North America, Europe, and India have the largest markets for finished hydrochlorothiazide products.
Has COVID-19 impacted the supply chain?
Yes, disruptions in API exports and manufacturing delays during the pandemic caused shortages and price increases.
What are the risks associated with hydrochlorothiazide supply?
Dependence on Asian API suppliers, quality issues, and regulatory restrictions pose ongoing risks.
References
[1] World Health Organization. (2022). Global API Production and Export Data.
[2] U.S. Food and Drug Administration. (2023). ANDA Approvals and Generic Drug Entry.
[3] European Medicines Agency. (2022). Regulatory Status of Hydrochlorothiazide in the EU.
